Cystic fibrosis (CF) is a life-limiting disease caused by defective or deficient 
cystic fibrosis transmembrane conductance regulator (CFTR) activity. The recent 
US Food and Drug Administration (FDA) approval of lumacaftor combined with 
ivacaftor (Orkambi) targets patients with the F508del-CFTR. The question 
remains: Is this breakthrough combination therapy the "magic-bullet" cure for 
the vast majority of patients with CF? This review covers the contemporary 
clinical and scientific knowledge-base for lumacaftor/ivacaftor and highlights 
the emerging issues from recent conflicting literature reports.